

uniQure to Present at Upcoming Investor Conferences in September

Lexington, MA and Amsterdam, the Netherlands, August 16, 2016 — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that members of its leadership team will present an overview of the company's programs and progress at several upcoming investor conferences. These meetings include the following:

➤ **CITI 11th Annual Biotech Conference**

Venue: The Mandarin Oriental Hotel, Boston MA

Presenter: Harald Petry, Ph.D., Chief Scientific Officer

Title, Date and Time: "Gene Therapy, A New Era" panel discussion, Wednesday, September 7, 1:00 p.m. EDT

➤ **Rodman & Renshaw 18th Annual Global Investment Conference**

Venue: The Lotte New York Palace Hotel, New York City

Presenter: Matthew Kapusta, Chief Financial Officer

Date and Time: Monday, September 12, 3:50 p.m. EDT

Webcast: <http://wsw.com/webcast/rshq26/qure>

➤ **Leerink Partners Rountable Series: Rare Disease & Immuno- Oncology**

Venue: The Lotte New York Palace Hotel, New York City

Presenter: Christian Meyer, M.D., Chief Medical Officer

Date and Time: Wednesday, September 28, 2:35 p.m. EDT

Webcast: <http://wsw.com/webcast/leerink27/qure>

The webcasts for the Rodman & Renshaw 18th Annual Global Investment Conference and the Leerink Partners Roundtable Series, also can be accessed by the link displayed in the "Events" section on the "Media" page of the uniQure website at: <http://www.uniqure.com/news/calendar-of-events/>. The replay of the webcast will be available one hour after the conclusion of the live events and archived on the uniQure website for at least 30 days following the webcast.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniqure.com

uniQure Forward-Looking Statement

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

Maria E. Cantor

Direct: 339-970-7536

Mobile: 617-680-9452

m.cantor@uniQure.com

Eva Mulder

Direct: +31 20 240 6103

Mobile: +31 6 52 33 15 79

e.mulder@uniQure.com